Trial | NCT06178718  Report issue

Title

A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules
A Phase 1, Single-center, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TNP-2092 Capsules, and the Food Effect on the Pharmacokinetics of TNP-2092 Capsules After Single-dose Oral Administration in Healthy Subjects

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    TNP-2092 ...

  • Study Participants

    58
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.
Study Started
Jun 06
2016
Primary Completion
Jul 30
2016
Study Completion
Jul 30
2016
Last Update
Dec 21
2023

Drug TNP-2092

The drug will be administered once in each group.

  • Other names: Rifaquizinone

Drug Placebo

The Placebo will be administered once in each group.

TNP-2092 capsules 100mg Experimental

TNP-2092 capsules 200mg Experimental

TNP-2092 capsules 400mg (Food effect study Group A) Experimental

After completed the single ascending dose study, the participant will convert to the food effect study. The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days.

TNP-2092 capsules 800mg Experimental

TNP-2092 capsules 1200mg Experimental

Food effect study Group B (TNP-2092 capsules 400 mg) Experimental

The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days.

Placebo Placebo Comparator

Criteria 

Inclusion Criteria:

Sex: male or female;
Age: 18-45 years, inclusive;
BMI: 19.0-26.0 kg/m2, inclusive;
Female subjects of childbearing potential must agree to practice abstinence or take effective contraceptive measures during the study and at least 70 days (10 weeks) after administration;
Male subjects must agree to practice abstinence or use condoms as a contraceptive measure during the study and at least 70 days (10 weeks) after administration;
Subjects whose clinical laboratory test results are within the normal range or whose test results are abnormal, but judged by the investigator to be of no clinical insignificance;
Those who do not smoke, or have smoked less than 5 cigarettes per day within 3 months before screening; those who do not drink alcohol, or have drunk less than - units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine) within 6 months before screening; those who have not smoked or drunk alcohol within 48 hours before admission to the study site;
Those who are fully informed of and understand this study, and have signed the Informed Consent Form;
Those who are willing to follow and able to complete all the study procedures.

Exclusion Criteria:

Those with symptoms or medical history of cardiovascular, digestive, respiratory, urinary, neurological, blood, immune, endocrine system diseases or tumor, mental illness, or any situation which, in the opinion of the investigator, may threaten the safety of the subjects or affect the correctness of the study results;
Pregnant or lactating women;
Those whose blood pressure above 150/90 mmHg or below 85/55 mmHg (supine position);
Those with regular use of any prescription/over-the-counter drugs, including vitamins, minerals, nutritional supplements or herbs, within 2 weeks before enrollment and during the study;
Those who are HIV positive, syphilis positive, hepatitis B surface antigen positive, hepatitis C antibody positive, and/or with a positive drug urine test result;
Those who have a history of alcohol or drug abuse in the past 10 years; Those with an allergic constitution, a history of allergic diseases or a history of drug allergy;
Those who have had beverages or foods containing methylxanthine (coffee, tea, coke, chocolate and energy drinks), grapefruit (fruit juice) and alcohol within 48 hours (2 days) before the clinical study;
Those who have taken any drug that changes the activity of liver enzymes within 28 days before taking the investigational product or during the study;
Those who have donated blood within 3 months before enrollment;
Those who have participated in any clinical studies within 3 months before enrollment;
Those who are the staff of the study site directly affiliated to this study or are their immediate family members. Immediate family members are defined as spouses, parents, children or siblings, whether related by blood or legally adopted;
Those who are employees of TenNor Therapeutics;
Other circumstances deemed by the investigator to be unsuitable for the subject to participate in this study.
No Results Posted